NCT06874166

Brief Summary

The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients affected by Becker (BMD) and Duchenne (DMD) muscular dystrophy, compared with a sample of patients affected by osteogenesis imperfecta (OI), and both compared with a control sample with typical development. The secondary aim is to study cortical activity at rest, by means of electroencephalography (EEG), to explore frequencies and time course of EEG responses. Moreover, the relationship between EEG activity and neuropsychological, dispositional and subjective measures will be explored through correlational analyses.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
19mo left

Started Sep 2025

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Sep 2025Dec 2027

First Submitted

Initial submission to the registry

February 17, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

March 13, 2025

Completed
6 months until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

March 13, 2025

Status Verified

March 1, 2025

Enrollment Period

2 years

First QC Date

February 17, 2025

Last Update Submit

March 11, 2025

Conditions

Keywords

Social CognitionDuchenne / Becker muscular dystrophyOsteogenesis Imperfecta (OI)EEGInterpersonal distanceInteroception

Outcome Measures

Primary Outcomes (6)

  • Interoception

    interoceptive index

    Day 1

  • Interpersonal distance

    Interpersonal comfort distance, measured in meters (m) within the virtual environment

    Day 1

  • Emotional processing

    Visual priming task performance

    Day 1

  • EEG power

    EEG alpha power

    once

  • EEG power

    EEG beta power

    Day 1

  • EEG power

    EEG theta power

    Day 1

Study Arms (3)

BMD/DMD group

Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant), over the age of four.

Other: Electroencephalography (EEG)Other: Social Cognition Tasks

OI group

Patients diagnosed with osteogenesis imperfecta, over the age of four.

Other: Electroencephalography (EEG)Other: Social Cognition Tasks

Control group

Participants without any neurological or psychiatric disorder, over the age of four.

Other: Electroencephalography (EEG)Other: Social Cognition Tasks

Interventions

Recording of resting state EEG will be collected

BMD/DMD groupControl groupOI group

Comfort-Distance Task: it will be used to measure the interpersonal comfort distance, the task will be implemented in immersive virtual reality environment Interoception will be measured through an auditory match task based on participants heart-beat A measure emotion processing will be collected through the emotion priming visual task, participants will be asked to detect trial by trial the target emotion which could be preceded by a congruent or incongruent visual priming

BMD/DMD groupControl groupOI group

Eligibility Criteria

Age4 Years+
Sexmale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

For the statistical power analysis the size of the effect reported in Candini et al., 2017 (η2p = 0.28) has been considered, about the effect of diagnostic features on the peripersonal space, and the effect reported by Garcia et al., 2023 (η2p = 0.20) about the differences between DMD/BMD patients and neurotypicals in social cognition. The calculation, performed separately for the two different effects, returns a sample size between 17 and 23 minimum patients per group.

You may qualify if:

  • Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant).
  • Patients diagnosed with osteogenesis imperfecta.
  • Control group: participants without any neurological or psychiatric disorder

You may not qualify if:

  • presence of comorbid diagnoses,
  • sensory deficit
  • specific condition that could prevent the application of the tests and tasks under study, such as: a) the need for PEG; b) the need for tracheostomy; c) the need for assisted ventilation.
  • cognitive level lower than 60.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Muscular Dystrophy, DuchenneOsteogenesis Imperfecta

Condition Hierarchy (Ancestors)

Muscular DystrophiesMuscular Disorders, AtrophicMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesGenetic Diseases, X-LinkedGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesOsteochondrodysplasiasBone Diseases, DevelopmentalBone DiseasesCollagen DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 17, 2025

First Posted

March 13, 2025

Study Start

September 1, 2025

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

March 13, 2025

Record last verified: 2025-03